Adverse Events of Nivolumab Plus Ipilimumab Versus Nivolumab Plus Cabozantinib: a Real-World Pharmacovigilance Study

No head-to-head clinical trials have compared the differences in adverse events (AEs) between nivolumab plus ipilimumab (NIVO-IPI) and nivolumab plus cabozantinib (NIVO-CABO) in the treatment of metastatic renal cell carcinoma (mRCC). We analysed the two largest real-world databases, the U.S. Food and Drug Administration Adverse Event Reporting System (FAERS) and the World Health Organization’s VigiBase, to elucidate the differences in AEs between NIVO-IPI and NIVO-CABO. In total, 40,376 and 38,022 records were extracted from FAERS and VigiBase, and 193 AEs were analysed. The reporting odds ratios (ROR) with 95